Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Operating Leases (2020 - 2025)

Historic Operating Leases for Adma Biologics (ADMA) over the last 6 years, with Q3 2025 value amounting to $9.4 million.

  • Adma Biologics' Operating Leases rose 600.11% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 600.11%. This contributed to the annual value of $8.6 million for FY2024, which is 1245.53% down from last year.
  • Per Adma Biologics' latest filing, its Operating Leases stood at $9.4 million for Q3 2025, which was up 600.11% from $9.3 million recorded in Q2 2025.
  • Adma Biologics' 5-year Operating Leases high stood at $10.9 million for Q2 2022, and its period low was $7.3 million during Q1 2022.
  • Its 5-year average for Operating Leases is $9.2 million, with a median of $9.3 million in 2025.
  • As far as peak fluctuations go, Adma Biologics' Operating Leases skyrocketed by 7217.65% in 2021, and later plummeted by 1253.29% in 2025.
  • Over the past 5 years, Adma Biologics' Operating Leases (Quarter) stood at $7.5 million in 2021, then soared by 43.44% to $10.7 million in 2022, then decreased by 8.64% to $9.8 million in 2023, then dropped by 12.46% to $8.6 million in 2024, then rose by 9.77% to $9.4 million in 2025.
  • Its last three reported values are $9.4 million in Q3 2025, $9.3 million for Q2 2025, and $8.3 million during Q1 2025.